Takeda Pharmaceutical (NYSE:TAK) Releases FY 2025 Earnings Guidance

Key Points

• Takeda Pharmaceutical updated its FY 2025 earnings guidance, projecting earnings per share of $3.36 and revenue of $31.3 billion.
• Morgan Stanley upgraded Takeda's rating from "equal weight" to "overweight", indicating increased confidence in the company's performance.
• The stock is currently trading around $14.32, with a market capitalization of $45.55 billion and a price-to-earnings ratio of 65.07.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.360-3.360 for the period. The company issued revenue guidance of $31.3 billion-$31.3 billion.

Takeda Pharmaceutical Stock Up 3.3%

NYSE:TAK traded up $0.45 during midday trading on Friday, reaching $14.17. The company had a trading volume of 6,215,654 shares, compared to its average volume of 4,714,807. The company has a current ratio of 1.16, a quick ratio of 0.52 and a debt-to-equity ratio of 0.60. The stock's fifty day simple moving average is $14.86 and its 200-day simple moving average is $14.51. The firm has a market capitalization of $45.09 billion, a price-to-earnings ratio of 47.23 and a beta of 0.22. Takeda Pharmaceutical has a 12-month low of $12.80 and a 12-month high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. On average, sell-side analysts anticipate that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TAK. Goldman Sachs Group Inc. raised its position in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after buying an additional 692,404 shares during the last quarter. AQR Capital Management LLC increased its stake in Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock worth $2,911,000 after buying an additional 59,442 shares during the period. Royal Bank of Canada grew its stake in Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. Finally, Focus Partners Wealth boosted its stake in Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock valued at $1,230,000 after acquiring an additional 3,239 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.